Satellite Symposia

Find below a list of all Satellite Symposia of EANM’23

Symposium 1
Monrol Nuclear Products Sunday, September 10, 2023 (13:15 - 14:45)

Hall E2

PSMA radioligand therapy of prostate cancer in clinical practice


Dr. Derya Tilki


1.15 – 1.20 pm
Welcome and Introduction; Dr. Derya Tilki

1.20 – 1.35 pm
Treatment Landscape of Advanced Prostate Cancer; Maria De Santis

1.35 – 1.50 pm
Importance of Next Generation Imaging in Prostate Cancer Management; Ken Herrmann

1.50 – 2.05 pm
Update of PSMA-Targeted Theranostics in Prostate Cancer; Joe O’Sullivan

2.05 – 2.35 pm
Case presentation; Dr. Derya Tilki
Multidisciplinary Panel Discussion; Maria De Santis, Ken Herrmann, Joe O’Sullivan, Dr. Derya Tilki

2.35 – 2.45 pm

Symposium 2
TELIX Sunday, September 10, 2023 (13:15 - 14:45)

Hall F1 - Available via Livestream and On Demand

Personalized Diagnostic in Urological Cancers: the Promise of Nuclear Medicine


Prof. Stefano Fanti, Nuclear Medicine Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy


13:15 – 13:35
Introduction: How PSMA PET dusted off the Management of Prostate Cancer
Prof. Stefano Fanti, Director of Nuclear Medicine Division and of PET Unit – Policlinico S.Orsola, Bologna, Italy

13:35 – 14:00
Prostate Cancer Imaging: is there only one PSMA-PET?
Dr. Macarena Rodríguez Fraile, Nuclear Medicine Clínica Universidad de Navarra, Pamplona, Spain

Next Generation Imaging in Urology: what’s new in Bladder and Kidney Cancers
Prof. dr. Karolien Goffin, Nuclear Medicine, University Hospital Leuven – KU Leuven, Leuven, Belgium

The Use of Artificial Intelligence in Prostate Cancer Management
Dr. László Papp, Center for Medical Physics and Biomedical Engineering (CMPBME), Medical University of Vienna, Vienna, Austria

Symposium 3
Springer Healthcare IME (supported by an educational grant from Lilly) Sunday, September 10, 2023 (13:15 - 14:45)

Hall F2

Preparing for the new era of neuroimaging for Alzheimer’s disease




Professor Frederik Barkhof (Amsterdam UMC, The Netherlands and University College London, UK)


13:15 – 13:20
Introduction (Frederik Barkhof)

13:20 – 13:30
Role of PET imaging in the disease modification era of Alzheimer’s disease; Silvia Morbelli (University of Genoa, Italy)

13:30 – 13:45
Advances in AD PET biomarkers; Alexander Drzezga (University of Cologne, Germany)

13:45 – 14:00
PET tracers: Which, when, how, who?; Lyduine Collij (Lund University, The Netherlands)

14:00 – 14:20
Q&A (Audience and panel discussion)

Summary (Frederik Barkhof)

Educational objectives

Explain the critical role of PET imaging in the new era of disease modification of Alzheimer’s disease

Appraise the utility of current and emerging PET biomarkers in clinical practice

Identify patterns from different PET tracers for a negative and positive AD brain and debate methods beyond binary amyloid PET interpretation

Symposium 4
Pfizer Sunday, September 10, 2023 (13:15 - 14:45)

Hall K - Available via Livestream and On Demand

Advancements in nuclear imaging for the diagnosis of cardiac amyloidosis



Sharmila Dorbala


Introduction to cardiac amyloidosis: from recognition to treatment
Speaker: René Rettl

Using cardiac scintigraphy for non-invasive diagnosis of ATTR-CM
Speaker: Sharmila Dorbala

Sharing practical approaches to accurate diagnosis: a case-based study
Speaker: Olivier Gheysens

Speaker: All faculty

Symposium 5
Spectrum Dynamics Monday, September 11, 2023 (13:15 - 14:45)

Hall E2

Reaching Higher Peaks in Digital SPECT Imaging

Join and hear VERITON-CT® and D-SPECT® users discuss how they are utilizing the latest groundbreaking technologies and how customers like you are finding their peak in digital SPECT imaging


Pr. Denis Agostini, MD, PhD. Head of Nuclear Medicine Department – University Hospital of Caen, CHU Caen, France

Dr. Miguel Ochoa Figueroa, MD, PhD. Specialist in Nuclear Medicine and Radiology – Linköping University Hospital, Sweden

Dr. Laetitia Imbert, PhD. Medical Physicist, Medical Physicist, Department of Nuclear Medicine – University Hospital of Nancy, CHRU Nancy , France

Pr. Antoine Verger, MD, PhD. Professor, Department of Nuclear Medicine – University Hospital of Nancy, CHRU Nancy, France

Symposium 6
GE HealthCare Monday, September 11, 2023 (13:15 - 14:45)

Hall C

Shaping the future with Total MI solutions


Mathias Goyen, Chief Medical Officer EMEA, GE HealthCare


Welcome and Introduction
Mathias Goyen, Chief Medical Officer EMEA, GE HealthCare

13:20–13:40 (incl. 5 minutes Q&A)
Advancing Next Generation Radiotracers to Help Improve Patient Outcomes
Paul Evans PhD, Head of Global R&D at GE HealthCare
Regina Young, Head of Global Market Access at GE HealthCare

13:40–14:00 (incl. 5 minutes Q&A)
How Omni Legend delivers increased flexibility to clinical applications
Prof. Miroslaw Dziuk, Affidea PET/CT Centre, Warsaw, Poland

14:00–14:20 (incl. 5 minutes Q&A)
StarGuideTM: the future of SPECT/CT is 3D
Tommi Noponen, Medical Physicist, Adj. Prof., Turku University Hospital, Finland

14:20–14:40 (incl. 5 minutes Q&A)
Patient-centered Diagnostic Imaging and Adapting to Clinical Needs with SIGNA™ PET/MR
Prof. Farshad Moradi, Stanford Health Care, USA

Symposium 7
Siemens Healthineers Monday, September 11, 2023 (13:15 - 14:45)

Hall F1 - Available via Livestream and On Demand

Answering to clinical needs in molecular imaging



Matt Shah, Marketing Operations Head, Siemens Healthineers


Transitioning to next-generation SPECT/CT: radiographers share their experience
Juho Kuukasjärvi, Oulu University Hospital, Finland
Joni Granlund, Oulu University Hospital, Finland

PET/CT Imaging of connectome and inflammation
Univ.-Prof. Dr. M. Hacker, AKH Vienna, Austria

Symposium 8
Curium Monday, September 11, 2023 (13:15 - 14:45)

Hall F2 - Available via Livestream and On Demand

PYLCLARI® [Piflufolastat (18F)] now in Europe: Sharing current perspectives for the diagnosis of prostate cancer


Prof. Dr. Jeroen van Moorselaar Chairman, Department of Urology Amsterdam UMC, Amsterdam, Netherlands

Assoc. Prof. Dr. Daniela E. Oprea-Lager Department of Radiology and Nuclear Medicine Amsterdam UMC, Amsterdam, Netherlands

Assoc. Prof. Dr. Juan Antonio Vallejo Casas Department of Nuclear Medicine University Hospital Reina Sofía, Córdoba, Spain

Symposium 9
PentixaPharm / Eckert & Ziegler Monday, September 11, 2023 (13:15 - 14:45)

Hall K - Available via Livestream and On Demand

The theranostics future is now: innovative diagnostic application and therapeutic potential of CXCR4




Prof. Ken Herrmann (Clinic of Nuclear Medicine University Hospital Essen)


CXCR4-directed Theranostics in Hematooncology
Speaker: Prof. Andreas Buck (Clinic of Nuclear Medicine University Hospital Würzburg)

Innovative CXCR4 directed diagnostic application in a common endocrine cause of hypertension
Speaker: Dr. Elisabeth Ng (Monash University Australia)

The Castus Trial: Aim, Design and Current Status
Speaker: Prof. Martin Gotthardt (University Medical Center Radboud University Nijmegen)

Panel Discussion

Symposium 10
United Imaging Tuesday, September 12, 2023 (13:15 - 14:45)

Hall E2

Transforming Precision Medicine: Pioneering Breakthroughs in Long Axial FOV and Next-Generation PET Technologies


Join us on a clinical journey utilizing innovative Long Axial Field of View (FOV) and Next-Generation PET Technologies. Witness their transformative influence on patient care, drug discovery, and personalized theranostics, shaping the future of precision medicine for all.


Joniada Doraku – Medical Doctor of Department of Nuclear Medicine, Ospedale Sacro Cuore-Don Calabria Hospital

Hongcheng Shi – Director of the Department of Nuclear Medicine, Zhongshan Hospital, Fudan University

Jeffrey Yap – Director of the Center for Quantitative Cancer Imaging, Huntsman Cancer Institute

Li Huo – Director of the Department of Nuclear Medicine, Peking Union Medical College Hospital

Richard Carson – Professor of Biomedical Engineering and Radiology, Yale University

Symposium 11
Novartis Tuesday, September 12, 2023 (13:15 - 14:45)

Hall K - Available via Livestream and On Demand

ADACAP Symposium at the EANM’23 World Meeting – Neuroendocrine tumour as an oncological entity





This promotional meeting is organised and fully funded by Advanced Accelerator Applications (ADACAP) International S.A., a Novartis company, and intended for healthcare professionals that treat patients with GEP-NETs

Lutetium (177Lu) oxodotreotide is indicated for the treatment of unresectable or metastatic, progressive, well differentiated (grades 1 and 2), somatostatin receptor positive GEP‑NETs in adults. Prescribing information can be found below, or at: Full EMA EPAR can be found at: Prescribing information may vary depending on local health authority approval in each country. Before prescribing any product, always refer to the Summary of Product Characteristics (SmPC) or product information approved in your local country.

Adverse events should be reported upon local legislation, to Accelerator Applications International S.A. at or through the pharmacovigilance link: Reporting forms and information can be found at

  • Dr Prakash Manoharan (Chair), The Christie NHS Foundation Trust, UK
  • Dr Nicola Fazio, European Institute of Oncology, Italy
  • Dr Jaume Capdevila, Vall d’Hebron Institute of Oncology (VHIO), Spain

Hall K, Level -2, Austria Center Vienna, Vienna, Austria


Tuesday 12 September 2023 | 13:15–14:15 CEST


60 minutes


To explore the oncological principles of neuroendocrine tumours (NETs)

To provide guidance on the management of patients with NETs through clinical case studies


Welcome and introduction
Dr Prakash Manoharan

General criteria for decision-making in patients with advanced GEP-NETS
Dr Nicola Fazio

Medical Cases – Presentation and Panel Discussion
Panel: Dr Nicola Fazio, Dr Jaume Capdevila

Close and thank you
Dr Prakash Manoharan

EU Abbreviated Prescribing Information
Lutathera 370 MBq/mL solution for infusion


One mL of solution contains 370 MBq of lutetium (177Lu) oxodotreotide at the date and time of calibration. The total amount of radioactivity per single-dose vial is 7 400 MBq at the date and time of infusion. Given the fixed volumetric activity of 370 MBq/mL at the date and time of calibration, the volume of the solution in the vial ranges between 20.5 and 25.0 mL in order to provide the required amount of radioactivity at the date and time of infusion. Physical characteristics: Lutetium-177 has a half-life of 6.647 days. Lutetium-177 decays by β- emission to stable hafnium-177 with the most abundant β- (79.3%) having a maximum energy of 0.498 MeV. The average beta energy is approximately 0.13 MeV. Low gamma energy is also emitted, for instance at 113 keV (6.2%) and 208 keV (11%). Excipient with known effect: Each mL of solution contains up to 0.14 mmol (3.2 mg) of sodium.

List of excipients: Acetic acid, Sodium acetate, Gentisic acid, Ascorbic acid, Pentetic acid, Sodium chloride, Sodium hydroxide, Water for injections;

Lutathera is indicated for the treatment of unresectable or metastatic, progressive, well-differentiated (G1 and G2), somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults.


  • Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
  • Established or suspected pregnancy or when pregnancy has not been excluded (see section 4.6).
  • Kidney failure with creatinine clearance <30 mL/min.

Pharmacotherapeutic group: Therapeutic radiopharmaceuticals, Other therapeutic radiopharmaceuticals, ATC code: V10XX04

Advanced Accelerator Applications, 8-10 Rue Henri Sainte-Claire Deville, 92500 Rueil-Malmaison, France

Detailed information on this medicinal product is available on the website of the European Medicines Agency

Symposium 12
ABX GmbH Tuesday, September 12, 2023 (13:15 - 14:45)

Hall F2 - Available via Livestream and On Demand

Translation of 18F-PSMA-1007 from research to routine clinical use



Prof. Dr. med. Kambiz Rahbar – Klinik für Nuklearmedizin, Universitätsklinikum Münster (UKM)

Speakers (presentation time 12-15 minutes)

PSMA-ligands: Introduction, Biology and its clinical peers
Univ.-Prof. Dr. med. Frederik L. Giesel –
Klinik für Nuklearmedizin, Universitätsklinikum Düsseldorf (UKD)

Pitfalls and phenotypes: PSMA in- and outside prostate cancer
Prof. Dr. Wolfgang Fendler – Klinik für Nuklearmedizin Essen

The advantages of low urinary clearance: what does the urologist gain from PSMA-imaging?
Prof. Dr. med. Tobias Maurer, FEBU – Universitätsklinikum Hamburg-Eppendorf

PSMA-1007: From a phase 3 clinical study to routine use in France
Prof. Dr. Pierre Olivier, Nuclear Medicine and Nancyclotep Molecular Imaging Platform, CHRU-Nancy, Université de Lorraine, Nancy, France

Biochemical Recurrence and PSMA Imaging: where are we today?
Prof. Dr. med. Kambiz Rahbar – Klinik für Nuklearmedizin, Universitätsklinikum Münster (UKM)


Get the latest updates and news about the EANM Congress in your inbox!

subscribe to our newsletter >